Lindsay Herbein
About Lindsay Herbein
Lindsay Herbein is the Director, Clinical Science Team Lead, Hematology at Bristol Myers Squibb and has over 15 years of experience in clinical research within the hematology field.
Current Roles at Bristol Myers Squibb and Celgene
Lindsay Herbein currently holds the position of Director, Clinical Science Team Lead, Hematology at Bristol Myers Squibb. She joined BMS in November 2019. Concurrently, she serves as the Director, Program Lead CRS, Clinical Research, Hematology at Celgene. Her dual roles at these prominent pharmaceutical companies highlight her versatility and expertise in clinical science and research leadership.
Professional Background at Celgene
Lindsay Herbein has an extensive background within Celgene, where she worked for approximately 12 years across different roles. She began her tenure as a Clinical Research Scientist from 2005 to 2010, followed by a position as a Senior Scientist, Clinical Research, from 2010 to 2016. She was later promoted to Principal CRS, Clinical Research, Hematology, serving from 2016 to 2017, before becoming the Director, Program Lead CRS, Clinical Research, Hematology. Her consistent rise through the ranks reflects her significant contributions and leadership within the organization.
Educational Background
Lindsay Herbein attended Kutztown University of Pennsylvania, where she earned a Bachelor of Science degree in Psychology. She studied at the institution from 1995 to 1999. Her educational background in psychology provides a foundational understanding of human behavior, which is beneficial in her clinical research roles within the hematology field.
Experience in Clinical Research and Hematology
With over 15 years of experience in clinical research focused on hematology, Lindsay Herbein has developed a robust expertise in this specialized medical field. Her career progression includes significant roles at Celgene and Bristol Myers Squibb, where she has been instrumental in leading clinical science teams and programs. Her deep knowledge and experience in hematology are critical assets in driving clinical research and program development.